Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma

NCT03201250 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT03201250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03201250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
Lead sponsor
University of Nebraska
Phase
Phase 1/2
Overall status
Terminated
Start date
February 21, 2018
Completion date
April 12, 2021
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory multiple myeloma, relapsed/refractory multiple myeloma